https://www.selleckchem.com/pr....oducts/zidesamtinib.
1), and 11 to 19mm in size (vs≤10mm). In patients with well- to moderately differentiated T1-2N0M0 NAD-NETs≤19mm confined to the mucosa/submucosa who underwent ET or surgery, the 5-year CSS was 100%. The 5-year OS was similar between the≤10-mm and 11- to 19-mm groups (86.6% vs 91.0%, P= .31) and the ET and surgery groups (87.4% vs 87.5%, P= .823). In NAD-NETs, invasion to the muscularis propria is the strongest risk factor for metastasis. In the absence of metastasis, in lesions with well/moderate differentiation and without muscle
Like
Comment
Share
